



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

### MINUTES OF THE TEAMS MEETING 22<sup>nd</sup> SEPTEMBER 2021

#### PRESENT:

Dr S Ramtoola (SR)	Consultant Physician, ELHT
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Chairperson)
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Ms Ana Batista	Specialist Pharmacist ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Ms F Iqbal	Senior Pharmacist NHS BwD CCG
Dr N Amir (NA)	Consultant Microbiologist, ELHT

#### IN ATTENDANCE:

Ms L Prince	Medicines Management Technician, EL CCG
-------------	---

#### 2021/098: APOLOGIES:

Dr T McKenzie (TM)	GP East Lancashire
--------------------	--------------------

#### 2021/099: DECLARATION OF INTEREST [relevant to agenda items]

None declared

#### 2021/084: MINUTES OF JULY Teams MEETING:

Spelling error: to be corrected on page 4 [Andexanet alfa]  
Accepted as a correct record

#### 2021/101: MATTERS ARISING:

##### a. Management of neuropathic pain [adults]

**ACTION:** Awareness of updated guidance to be highlighted to pain team by VG.

##### b. ELMMB membership

**ACTION:** Agreed to review group membership and update via divisional directors to be asked to review their members and suggest a nominated person to attend future meetings.



## **2021/102 NEW PRODUCT REQUEST – PARECOXIB**

Requested for short-term treatment of postoperative pain in adults (administration in theatres). Also, pain management for patients with poor absorption or nil by mouth as an alternative to IV diclofenac.

**Resolved: Parecoxib to be included on formulary Traffic Light: RED**

## **2021/103 NEW PRODUCT REQUEST – CEFIDEROCOL**

Requested by microbiology for use in multi-drug resistant infections where other agents are unsuitable/not susceptible, or as part of combination therapy with other agents for resistant organisms

**Resolved: Cefiderocol included on formulary for use only on the advice of Consultant Microbiologist. Traffic Light: RED**

## **2021/104: LSCMMG CONSULTATIONS (for September LSCMMG)**

[Responses were due 1<sup>st</sup> September]

- Glycopyrronium bromide oral solution for hypersalivation in Parkinson's disease.
- Idarucizumab for rapid reversal of anticoagulant effects of dabigatran.
- Primary Care Guideline for the use of SGLT-2 Inhibitors in reduced ejection fraction heart failure.

## **2021/105: LSCMMG RECOMMENDATIONS (for October LSCMMG)**

- Liothyronine RAG position  
ELMMB Support RAG status, but it was suggested that the wording should read 'symptom' and not 'disease'
- Oxygen for cluster headache position statement  
ELMMB support the Position Statement
- Bevespi Aerosphere® New Medicine Assessment
- Trixeo Aerosphere® New Medicine Assessment
- Guidance on the consensus approaches to managing Palliative Care Symptoms. Clinical Practice Summary  
Note: The summary will need to be reviewed in line with ELMMB formulary.

## **Comments to be sent to LSCMMG**



**2021/106: LSCMMG recommendations (from July LSCMMG)**

None

**2021/107: JOINT COMMITTEE OF CCGs [JCCCG] COMMISSIONING DECISIONS**

None

**2021/108: FORMULARY UPDATES**

**Vitamin D:** ELHT to switch from use of ProD3 to Invita® D3 25,00iu amps in paediatrics  
**Traffic Light: AMBER**

**WaveSense Jazz:** agreed as a pilot last year for use in ELHT maternity services for gestational diabetes where the reporting platform was provided free-of-charge. ELHT to discuss and review continuation of use outside of meeting.

**Blood Glucose Testing Strips Approved Formulary Choices:** Contour Plus Blue meter has been launched and has a feature enabling it to connect via Bluetooth to the free Contour Diabetes App. It uses the **Contour® Plus** test strips which are already on formulary. The meter will be added as an approved meter to formulary choice alongside the Tee2+ meter for Type 1 or 2 diabetics on insulin alone or on insulin +oral therapy. The Contour Plus strips are competitively priced along with Tee2 strips and offer significant cost savings.

**Prescribing Hot Topic to be circulated and Choice of Meters table to be updated.**

**Ronapreve** - casirivimab and imdevimab to be included in formulary for patients hospitalised due to COVID-19. Blueteq approved

**Traffic Light: RED**

**Sarilumab** - to be included in formulary for the treatment of suspected or confirmed COVID-19.

**Traffic Light: RED**

**Resolved: Formulary will be amended accordingly.**

**2021/109: ELHT Symptom management and care in the last days of life for patients with COVID-19 – updated document.**

ACTION: VG to discuss document with palliative care specialists

**2021/110: NICE RECOMMENDATIONS (from July)**

Enzalutamide – recommended as an option for use in treating hormone-sensitive metastatic prostate cancer TA712 is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**



Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (TA714) – terminated appraisal

**Traffic Light: BLACK**

Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715) are recommended as options [all with methotrexate] by NICE. Approved in line with NICE

CCG Commissioned Blueteq form required

**Traffic Light: RED**

Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716) is recommended as an option by NICE. Approved in line with NICE.

NHSE England Commissioned

**Traffic Light: RED**

Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (TA717) – terminated appraisal

**Traffic Light: BLACK**

Ixekizumab for treating axial spondyloarthritis (TA718) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned Blueteq form required

**Traffic Light: RED**

Secukinumab for treating non-radiographic axial spondyloarthritis (TA719) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned Blueteq form required

**Traffic Light: RED**

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249) Updated

CCG Commissioned

**Traffic Light: GREEN**

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) Updated

CCG Commissioned

**Traffic Light: GREEN**

Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275) Updated

CCG Commissioned

**Traffic Light: GREEN**

Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355) Updated

CCG Commissioned

**Traffic Light: GREEN**



**2021/111 NICE HST recommendation (from July)**

Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)

HST15 acknowledged by ELMMB

**2021/112: NICE RECOMMENDATIONS (from August)**

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721) is not recommended as an option by NICE.

**Traffic Light: BLACK**

Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722) is recommended as an option by NICE.

Approved in line with NICE

NHS England Commissioned

**Traffic Light: RED**

Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139) Updated

**AOB**

SR requested that Lyumjev [insulin lispro] be included in formulary whilst awaiting updated anti-hyperglycaemic guidelines. Approved by LSCMMG in March 2021 –

**Traffic Light GREEN restricted**

**STANDING ITEMS**

**2021/096: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA  
MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES –June 2021**

Minutes acknowledged

**2021/113: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA  
MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES JULY 2021**

Minutes acknowledged

**2021/114 FOR ACTION/INFORMATION: LANCASHIRE & SOUTH  
CUMBRIA NHS FOUNDATION TRUST DRUG & THERAPEUTICS  
COMMITTEE MINUTES JULY 2021**

Minutes acknowledged

**DATE OF NEXT MEETING – Wednesday 20<sup>th</sup> October 2021 12.45pm via  
'Microsoft Teams'**



**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 15th SEPTEMBER 2021**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
2019/131	<b>Treatment of Vitamin B12 Deficiency Draft</b> – pathway to be developed. Awaiting costing to measure B12.	LR/JV	Nov 21
2021/086	<b>New Product Request (unlicensed) – Short Chain Fatty Acids</b> – the directorate to provide updated information on dosing, length of treatment, costs & expected patient numbers per year	SH /VG	Oct 21
2021/094	<b>Steroid Emergency Card</b> SJ to attend next medicines safety meeting at the Trust and outcomes to be brought to next meeting in October	VG/SJ	Oct 21
2021/101a	<b>Management of Neuropathic Pain [adults]</b> Awareness of updated guidance to be highlighted to pain team	VG	Oct 21
2021/101b	<b>ELMMB Membership</b> Divisional directors to be asked to review their members and suggest a nominated person to attend future meetings.	LR/VG	Oct 21
2021/109	<b>ELHT Symptom management and care in the last days of life for patients with COVID-19</b> VG to discuss document with palliative care specialists	VG	Oct 21